Share this article
Share this article
DUBLIN, April 22, 2021 /PRNewswire/ Irish cell engineering company, Avectas, is leading a consortium which will invest €7.23 million, including €4.4 million awarded under the Irish Government s Disruptive Technology Innovation Fund (DTIF), to develop a high-throughput scale of its proprietary cell engineering platform Solupore®. With consortium partners Bluebridge Technologies and NIBRT, the project expands Avectas development towards commercialising an advanced large-scale, digitalised cell engineering platform optimised to manufacture off-the-shelf cell-based therapies for cancer treatment.
The Disruptive Technologies Innovation Fund (DTIF) is a €500 million fund established under Project Ireland 2040 and run by the Department of Enterprise Trade and Employment with support from Enterprise Ireland.
Government announce €95m for ground-breaking projects under Disruptive Technologies Fund merrionstreet.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from merrionstreet.ie Daily Mail and Mail on Sunday newspapers.
Irish medtechs continue to innovate in a radically changed environment Independent.ie 20/12/2020 Alan Hobbs
The past year delivered a perfect storm for Irish start-ups with the dual challenge of dealing with the impact of Covid-19 on their businesses and the impending Brexit deadline.
We ve seen first-hand how companies responded by being agile, competitive and innovative in finding new ways to sustain their business and keep teams together in a radically changed environment.
Covid-19 has created obvious challenges but interestingly some opportunities, both economically and socially.
Despite the pandemic, and the immense toll it has taken, the Irish start-up community has continued to innovate, to create jobs and to adapt.